FDA Wins Appeal On Drug Access For Terminally Ill Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
En banc review concludes there is no constitutional right to receive experimental drugs, reversing a previous ruling, but Abigail Alliance pledges to take case to the Supreme Court.
You may also be interested in...
Access To Investigational Drugs Under FDA Proposed Rule Depends On Size Of Treatment Group
Agency also details criteria for charging for investigational drugs in separate proposed rule.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.